118.30
price down icon0.15%   -0.18
after-market Handel nachbörslich: 118.83 0.53 +0.45%
loading
Schlusskurs vom Vortag:
$118.48
Offen:
$118.08
24-Stunden-Volumen:
4.46M
Relative Volume:
0.69
Marktkapitalisierung:
$146.79B
Einnahmen:
$28.80B
Nettoeinkommen (Verlust:
$6.31B
KGV:
23.53
EPS:
5.0273
Netto-Cashflow:
$9.37B
1W Leistung:
+0.04%
1M Leistung:
+5.12%
6M Leistung:
+11.94%
1J Leistung:
+37.85%
1-Tages-Spanne:
Value
$117.07
$119.07
1-Wochen-Bereich:
Value
$115.80
$119.33
52-Wochen-Spanne:
Value
$85.60
$121.83

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
17,600
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Vergleichen Sie GILD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
118.30 147.01B 28.80B 6.31B 9.37B 5.0273
Drug Manufacturers - General icon
LLY
Lilly Eli Co
826.57 728.24B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
191.17 459.63B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
226.22 404.77B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
129.97 252.16B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.11 211.56B 63.43B 16.42B 14.72B 6.4861

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-19 Hochstufung Daiwa Securities Neutral → Outperform
2025-08-08 Hochstufung Truist Hold → Buy
2025-07-25 Hochstufung Needham Hold → Buy
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-03-04 Bestätigt Oppenheimer Outperform
2025-02-18 Hochstufung Deutsche Bank Hold → Buy
2025-02-13 Hochstufung DZ Bank Hold → Buy
2025-01-10 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Buy
2024-11-08 Herabstufung Maxim Group Buy → Hold
2024-10-21 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-10-07 Hochstufung Wells Fargo Equal Weight → Overweight
2024-07-08 Hochstufung Raymond James Mkt Perform → Outperform
2024-05-01 Bestätigt Maxim Group Buy
2024-04-24 Hochstufung HSBC Securities Reduce → Hold
2024-02-22 Herabstufung Truist Buy → Hold
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
Oct 15, 2025

Gilead presents new HIV research data at EACS 2025 – driving scientific innovation in treatment and prevention - European AIDS Treatment Group

Oct 15, 2025
pulisher
Oct 15, 2025

Gilead to present data on potential first weekly oral treatment for HIV - Clinical Trials Arena

Oct 15, 2025
pulisher
Oct 15, 2025

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials - Benzinga

Oct 15, 2025
pulisher
Oct 15, 2025

Gilead highlights HIV pipeline at European AIDS Conference - The Pharma Letter

Oct 15, 2025
pulisher
Oct 15, 2025

Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com

Oct 15, 2025
pulisher
Oct 15, 2025

ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial - Seeking Alpha

Oct 15, 2025
pulisher
Oct 15, 2025

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention - BioSpace

Oct 15, 2025
pulisher
Oct 15, 2025

Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference - GuruFocus

Oct 15, 2025
pulisher
Oct 15, 2025

Gilead presents new HIV research data at European AIDS Conference - StreetInsider

Oct 15, 2025
pulisher
Oct 14, 2025

Chinese Research Org. Says Gilead Infringed COVID Patent - Law360

Oct 14, 2025
pulisher
Oct 14, 2025

Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter

Oct 14, 2025
pulisher
Oct 13, 2025

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga

Oct 13, 2025
pulisher
Oct 13, 2025

Gilead to present promising data for Trodelvy in breast cancer at ESMO - Investing.com

Oct 13, 2025
pulisher
Oct 13, 2025

Gilead to present Trodelvy breast cancer data at ESMO 2025 - StreetInsider

Oct 13, 2025
pulisher
Oct 13, 2025

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' - Benzinga

Oct 13, 2025
pulisher
Oct 13, 2025

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 - Business Wire

Oct 13, 2025
pulisher
Oct 13, 2025

Yousif Capital Management LLC Sells 2,855 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 13, 2025
pulisher
Oct 13, 2025

Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer - firstwordpharma.com

Oct 13, 2025
pulisher
Oct 13, 2025

ADAPT: Accelerating Disability Awareness & Progress Together - Gilead Sciences

Oct 13, 2025
pulisher
Oct 12, 2025

OFI Invest Asset Management Sells 86,817 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Transcendent Capital Group LLC Invests $432,000 in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Gilead Sciences, Inc. $GILD Position Boosted by Sivik Global Healthcare LLC - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Natural Investments LLC Has $317,000 Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Lmcg Investments LLC Has $1.97 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025
pulisher
Oct 11, 2025

How Investors Are Reacting To Gilead Sciences (GILD) Expanding HIV Drug Access and Delaying Generics - Sahm

Oct 11, 2025
pulisher
Oct 11, 2025

How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline - Yahoo Finance

Oct 11, 2025
pulisher
Oct 11, 2025

How the Story Behind Gilead Is Evolving in Light of Key Analyst and Industry Updates - Yahoo Finance

Oct 11, 2025
pulisher
Oct 11, 2025

Conning Inc. Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Fourpath Capital Management LLC Reduces Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

3Chopt Investment Partners LLC Acquires 3,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Gilead Sciences, Inc. $GILD Shares Sold by Aberdeen Group plc - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Gilead Sciences (NASDAQ:GILD) Stock Unloaded Rep. Val T. Hoyle - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Gilead: Incorporating Longer Biktarvy Runway - Morningstar

Oct 10, 2025
pulisher
Oct 10, 2025

Gilead's HIV Portfolio Has a Long Runway and Supports a Wide Moat - Morningstar

Oct 10, 2025
pulisher
Oct 10, 2025

Cantor Fitzgerald Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Blair William & Co. IL Decreases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Trifecta Capital Advisors LLC Has $339,000 Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

TFR Capital LLC. Makes New $283,000 Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Callan Family Office LLC Purchases 63,300 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Tectonic Advisors LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Maryland State Retirement & Pension System Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

US Bancorp DE Sells 22,670 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Vontobel Holding Ltd. Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Can Gilead Sciences Inc. hit a new high this monthWeekly Investment Report & Fast Moving Trade Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Real time social sentiment graph for Gilead Sciences Inc.July 2025 Setups & Weekly Breakout Stock Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - BioSpace

Oct 09, 2025
pulisher
Oct 09, 2025

"Taking possibility back" across oncology’s toughest frontiers - statnews.com

Oct 09, 2025
pulisher
Oct 09, 2025

Gilead Sciences To Release Third Quarter 2025 Financial Results On Thursday, October 30, 2025 - TradingView

Oct 09, 2025
pulisher
Oct 09, 2025

Oklahoma City NewsThe Oklahoman - FinancialContent

Oct 09, 2025
pulisher
Oct 09, 2025

RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD) - The Globe and Mail

Oct 09, 2025

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general PFE
$24.39
price down icon 0.53%
$297.32
price up icon 1.18%
drug_manufacturers_general SNY
$48.96
price down icon 0.53%
drug_manufacturers_general NVO
$56.72
price up icon 0.11%
drug_manufacturers_general MRK
$84.11
price down icon 0.70%
Kapitalisierung:     |  Volumen (24h):